Pharmadrug Inc.
PHRX
CNSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -69.10% | 597.12% | |||
| Depreciation & Amortization | 0.00% | -1.10% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -61.47% | 317.95% | |||
| Operating Income | 61.47% | -317.95% | |||
| Income Before Tax | -37.51% | -62.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -37.51% | -62.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 0.00% | 0.00% | |||
| Net Income | -40.33% | -70.89% | |||
| EBIT | 61.47% | -317.95% | |||
| EBITDA | 69.10% | -597.12% | |||
| EPS Basic | -11.11% | -80.00% | |||
| Normalized Basic EPS | 40.00% | -233.33% | |||
| EPS Diluted | -11.11% | -80.00% | |||
| Normalized Diluted EPS | 40.00% | -233.33% | |||
| Average Basic Shares Outstanding | 24.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 24.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||